This inventor holds 1 USPTO granted patent and 1 published patent application, plus 1 CIPO patent and 1 EPO patent. Top assignee: Klinge Pharma Gmbh. Active years: 1996.
Company Filing History:
Years Active: 1996
Title: The Innovations of Karl Schwitzer
Introduction
Karl Schwitzer is a notable inventor based in Munich, Germany. He has made significant contributions to the field of pharmaceuticals, particularly with his work on Lifibrol. His innovative approach has led to advancements that benefit both the industry and consumers.
Latest Patents
Karl Schwitzer holds a patent for a new modification of Lifibrol. This modification is characterized by a melting point of 132°C to 138°C, with a preferred range of 134°C to 136°C. The primary peak in the IR spectrum is noted at a wave number of 3,200 to 3,400, ideally at 3,250 to 3,350. This new modification, referred to as modification II, allows for excellent crystallization, making it feasible to formulate tablets on a large industrial scale while maintaining acceptable size and high stability.
Career Highlights
Karl Schwitzer is associated with Klinge Pharma GmbH, where he has been instrumental in developing pharmaceutical products. His expertise and innovative mindset have positioned him as a valuable asset in the company.
Collaborations
Throughout his career, Karl has collaborated with talented individuals such as Artur Burger and Anita Lettenbichler. These partnerships have fostered a creative environment that encourages the development of groundbreaking solutions in the pharmaceutical industry.
Conclusion
Karl Schwitzer's contributions to the field of pharmaceuticals, particularly through his patent on Lifibrol, highlight his innovative spirit and dedication to improving industrial processes. His work continues to influence the industry positively.